April 10th 2024
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
April 8th 2024
The FDA has accepted for review the new drug application for SH-201 for the treatment of patients with certain forms of leukemia and other cancers.
The FDA has granted breakthrough therapy designation to sunvozertinib for patients with locally advanced or metastatic NSCLC with an EGFR exon 20 insertion mutation.
April 7th 2024
Adjuvant treatment with the personalized neoantigen vaccine, autogene cevumeran, delayed pancreatic cancer recurrence in pancreatic ductal adenocarcinoma.
April 6th 2024
Eduardo M. Sotomayor, MD, discusses updates in the treatment of hematologic malignancies, highlighting research on antibody-drug conjugate and bispecific antibody combinations.
April 5th 2024
RNX-051 displays impact on bacterial biomass in patients with right-sided colorectal cancer and right-sided colon polyps/adenomas.
April 4th 2024
Eduardo M. Sotomayor, MD, expands on the evolving treatment paradigm for hematologic malignancies, highlighting treatment with CAR T-cell therapy.
Bernard H. Bochner, MD, FACS, discusses updates in the treatment of muscle-invasive bladder cancer and ongoing trials in the space.
Positive phase 2 findings for CAN-2409 plus valacyclovir in pancreatic ductal adenocarcinoma have been reported.
April 3rd 2024
Carlos L. Arteaga, MD, discusses the utility of vepdegestrant alone or in combination in patients with ER-positive, HER2-negative advanced breast cancer.
Daniel P. Petrylak, MD, discusses the importance of molecularly-driven clinical trials and ongoing research with novel therapeutics in urothelial carcinoma.
April 1st 2024
Bernard H. Bochner, MD, FACS, highlights advancements in early-stage muscle-invasive bladder cancer and the necessity for multimodality approaches.
Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.
March 31st 2024
Daniel P. Petrylak, MD, discusses advancements in the treatment of patients with bladder cancer.
March 30th 2024
Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.
March 27th 2024
TTFields plus supportive care improved time to intracranial progression in patients with brain metastases from non–small cell lung cancer.
Investigators emphasize the importance of firming a widely understood definition of unmet needs in cancer care due to their impact on drug approvals.
March 26th 2024
Pierre Gholam, MD, discusses primary considerations for the first-line treatment of patients with advanced, unresectable HCC.
March 25th 2024
Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC.
March 22nd 2024
The EMA’s CHMP has recommended the approval of enzalutamide with or without androgen deprivation therapy in biochemically recurrent nmHSPC.